Muireann Bolger

Key details

Muireann Bolger is deputy editor of World Intellectual Property Review and Life Sciences Intellectual Property Review in London, where she covers trademarks, brands, as well as wider developments across the intellectual property sector.

She regularly attends and covers major IP conferences around the world, reporting on the latest legal, commercial and policy developments and interviewing leading figures from across the sector. She has also co-authored industry reports with leading IP organisations, including the International Trademark Association (INTA).

She is the editor of the website’s Community & Inclusion channel and the annual Influential Women in IP list, which celebrates the achievements and contributions of leading women across the IP sector.

Originally from Ireland, Muireann has nearly two decades of experience reporting on brand developments, strategy, and wider business issues.

In her current role, she writes and edits news and analysis for an international audience of IP professionals, while also championing inclusion within the profession.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 415

Articles by Muireann Bolger

FTC wades into Medtronic bipolar energy case
Americas
Commission says that medical device maker’s arguments have broad implications for antitrust enforcement | Dispute concerns alleged exclusive-dealing and bundling arrangements.   5 July 2023
FTC weighs in on AbbVie antitrust litigation
Americas
Commission argues that a New York federal court erred in its finding that deals between an AbbVie unit and generic manufacturers were justified | US Supreme Court previously ruled that “unjustified” reverse payments can violate the antitrust laws.   22 June 2023
Bausch targets Israeli firm in skin treatment dispute
Americas
Pharma company claims infringement of both patents that cover the blockbuster treatment | Generic version has been in motion since May last year.   22 June 2023
Americas
Both drug treatments inhibit a protein called Bruton’s tyrosine kinase that can trigger cancer | Lawsuit comes in wake of patent grant for disputed drug | New study caused headaches for AbbVie’s subsidiary.   20 June 2023
Americas
The three-year dispute revolved around proposed generic versions of a drug used to offset the effects of muscle relaxants | Pharma giant can retain patent until January 2026.   15 June 2023
Americas
Deal thought to be aimed at helping pharma giant attain sales target as patents start to expire | Israeli drugmaker will join with Icelandic firm to unveil a copycat version of blockbuster treatment by 2025.   14 June 2023
Americas
Win marks latest leg of cross-Atlantic litigation feud over devices that stop internal bleeding | Medical device maker garnered success against rival in the US and Germany but failed to secure an injunction in one European country.   13 June 2023
article
Case involved the alleged monopolisation of an opioid addiction treatment | More than 40 attorneys general had filed complaints against the pharma company.   6 June 2023
Pharma
Big pharma company picks pan-European venue for next leg of global dispute | IT issues potentially behind new court's low revocation count | Nearly half a million opt-outs registered.   6 June 2023
Pharma
Case concerned the interpretation of a key requirement of the US Patent Act | Amgen’s ‘roadmap’ held to describe step-by-step its own trial-and-error method for finding functional antibodies.   18 May 2023

Not finding what you're looking for, please try resetting your applied search and filters,
or try the
full site search.